Scholarlink

<p>Alzheimer’s disease (AD) is the most common form of dementia, which can be debilitating and affect the patients’ quality of life. Saffron (<i>Crocus Sativus</i> L.) is a plant growing in various countries with potential anti-inflammatory, and antioxidant effects. This study aims to systematically review the role of saffron as a therapeutic agent or supplementation in patients with AD. We searched PubMed, Scopus, Embase, and Web of Science databases on 5/1/2023. Clinical studies that reported the effectiveness and/or safety of saffron in patients with AD are considered for inclusion. 565 studies were identified in the initial comprehensive search, and finally, only 4 studies met the eligibility criteria. All the studies were conducted in Iran. Studies showed that saffron has comparable efficacy in cognitive outcomes with approved drugs for AD, donepezil, and memantine; however, supplementation with saffron does not add beneficial effects in this regard. There were no considerable safety issues. Saffron is suggested as a potential herbal therapeutic agent in AD based on limited available evidence. Limitations of the evidence such as the small sample sizes as well as the skimp number of the included studies suggested prudence in clinical recommendations based on the findings of this study; however, this systematic review shed light on the necessity of conducting future trials on this topic.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Saffron’s promise: a systematic review of its role in Alzheimer's treatment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月24日

查看全文
  • Ali Norouzi,
  • Armin Jabraeilipour,
  • Nadia Doustar,
  • Hadi Sahrai,
  • Maryam Saberivand,
  • Reza Mosaddeghi-Heris,
  • Hesam Shahabifard,
  • Mahnaz Talebi,
  • Sarvin Sanaie,
  • Amirreza Naseri

摘要

Alzheimer’s disease (AD) is the most common form of dementia, which can be debilitating and affect the patients’ quality of life. Saffron (Crocus Sativus L.) is a plant growing in various countries with potential anti-inflammatory, and antioxidant effects. This study aims to systematically review the role of saffron as a therapeutic agent or supplementation in patients with AD. We searched PubMed, Scopus, Embase, and Web of Science databases on 5/1/2023. Clinical studies that reported the effectiveness and/or safety of saffron in patients with AD are considered for inclusion. 565 studies were identified in the initial comprehensive search, and finally, only 4 studies met the eligibility criteria. All the studies were conducted in Iran. Studies showed that saffron has comparable efficacy in cognitive outcomes with approved drugs for AD, donepezil, and memantine; however, supplementation with saffron does not add beneficial effects in this regard. There were no considerable safety issues. Saffron is suggested as a potential herbal therapeutic agent in AD based on limited available evidence. Limitations of the evidence such as the small sample sizes as well as the skimp number of the included studies suggested prudence in clinical recommendations based on the findings of this study; however, this systematic review shed light on the necessity of conducting future trials on this topic.